

**QUALITY ASSESSMENT OF PHARMACOTHERAPY OF PATIENTS  
WITH HYPERTENSION IN THE CITY OF GENICHESK,  
KHERSON REGION, UKRAINE**

Iakovlieva L., Berdnyk O., Tkachova O., Gerasymova O., Bahlai T.

National University of Pharmacy, Kharkiv, Ukraine

iakovlievalv@gmail.com

**Objectives:** a clinical and economic analysis of pharmacotherapy of patients with hypertension was performed.

**Methods:** ABC analysis, frequency analysis of drug prescriptions, formal VEN analysis of drugs used to pharmacotherapy patients with GC. The following medical documents were used for VEN-analysis: national list of major drugs of Ukraine (National List), State Form of Medicines of Ukraine issue 13 (DFLZU №13), Unified Clinical Protocol of Medical Care (UKPMD), NICE guideline, and BNF. The group of patients with the main diagnosis of GC was 51 patients aged 38 to 81 years. 37 INN drugs were used to treat patients, which corresponded to 68 trade names (TN), which were prescribed to patients 149 times.

**Results:** The average number of prescribed TN per patient was 2.9 TN. According to the ABC analysis, it was found that the most expensive group A included 27 TN, which spent 79.7% of the funds (\$ 1292.4) of the total cost of pharmacotherapy of 51 patients (\$ 1621.73). The cost of treatment was calculated for three months. Metformin 1000 mg took first place among drugs in terms of price. The cost was \$ 104.45. In total, group A included only three non-antihypertensive drugs: Metformin 1000 mg and 800 mg, Atorvastatin 20 mg. \$ 195.19 (12.04%) was used for their purpose. Analysis of TOP-15 drugs by frequency of administration by pharmacotherapeutic groups showed that they are mainly antihypertensive drugs (11 TH), two combined antihypertensive drugs, antiplatelet acetylsalicylic acid, and oral hypoglycemic agent based on INN Metformin. Formal VEN-analysis confirmed the feasibility of prescribing drugs. The analysis showed that of the 37 INNs studied, 8 INNs were recommended by all regulatory documents: Amlodipine, Verapamil, Bisoprolol, Enalapril, Acetylsalicylic Acid, Metoprolol, Spironolactone, Simvastatin, and Metformin.

**Conclusions:** VEN analysis did not reveal any INNs that are not included in all regulations.